荧光金属蛋白酶底物在癌症检测中的应用潜力。
Potential of fluorescent metalloproteinase substrates for cancer detection.
机构信息
Program in Vascular Biology and Department of Surgery, Children's Hospital Boston, Harvard Medical School, Boston, MA 02115, USA.
出版信息
Clin Biochem. 2011 Dec;44(17-18):1434-9. doi: 10.1016/j.clinbiochem.2011.09.016. Epub 2011 Oct 6.
Abstract
OBJECTIVES
MMP-2, MMP-9, their complexes and ADAM12 are detected in the urine of breast cancer patients and predict disease status. We assessed the use of FRET-based substrates in an assay to distinguish breast cancer patients from controls.
DESIGN AND METHODS
Substrates with varying specificities for MMP-9 and MMP-2 and several ADAMs were screened. Flsub21 and Flsub13, substrates for ADAM12 and ADAM8 respectively, were studied.
RESULTS
Flsub21 and Flsub13 cleavage activities were detected in the urine of patients with invasive and metastatic breast cancers at significantly higher frequencies compared to controls. Our model predicted probabilities of 90% when both Flsub21 and Flsub13 were positive, 65% when Flsub21 alone was positive, 55% when Flsub13 alone was positive and 20% when both substrates were negative.
CONCLUSIONS
These data suggest the potential utility of FRET substrates to non-invasively identify invasive and/or metastatic breast cancer.
摘要
目的
MMP-2、MMP-9、它们的复合物和 ADAM12 可在乳腺癌患者的尿液中检测到，并可预测疾病状态。我们评估了基于 FRET 的底物在区分乳腺癌患者和对照中的应用。
设计与方法
筛选了针对 MMP-9 和 MMP-2 以及几种 ADAMs 的特异性不同的底物。分别研究了 ADAM12 和 ADAM8 的底物 Flsub21 和 Flsub13。
结果
与对照组相比，侵袭性和转移性乳腺癌患者的尿液中 Flsub21 和 Flsub13 的裂解活性明显更高。当 Flsub21 和 Flsub13 均为阳性时，我们的模型预测概率为 90%，当 Flsub21 单独为阳性时预测概率为 65%，当 Flsub13 单独为阳性时预测概率为 55%，而当两种底物均为阴性时预测概率为 20%。
结论
这些数据表明 FRET 底物具有非侵入性识别侵袭性和/或转移性乳腺癌的潜在用途。
相似文献
1
Potential of fluorescent metalloproteinase substrates for cancer detection.荧光金属蛋白酶底物在癌症检测中的应用潜力。
Clin Biochem. 2011 Dec;44(17-18):1434-9. doi: 10.1016/j.clinbiochem.2011.09.016. Epub 2011 Oct 6.
2
Sentinel node biopsy in invasive breast cancer and ductal carcinoma in situ.
Bol Asoc Med P R. 2003 Mar-Apr;95(2):23-4, 29.
3
MR mammography is useful in the preoperative locoregional staging of breast carcinomas with extensive intraductal component.乳腺磁共振成像对伴有广泛导管内成分的乳腺癌术前局部区域分期很有用。
Eur J Radiol. 2007 May;62(2):273-82. doi: 10.1016/j.ejrad.2006.12.004. Epub 2007 Jan 12.
4
Detection of micrometastatic breast cancer by means of real time quantitative RT-PCR and immunostaining in perioperative blood samples and sentinel nodes.通过实时定量逆转录聚合酶链反应和免疫染色检测围手术期血样和前哨淋巴结中的微转移乳腺癌。
Int J Cancer. 2003 Sep 10;106(4):611-618. doi: 10.1002/ijc.11295.
5
Identification and transfer of spatial transcriptomics signatures for cancer diagnosis.用于癌症诊断的空间转录组学特征的识别和转移。
Breast Cancer Res. 2020 Jan 13;22(1):6. doi: 10.1186/s13058-019-1242-9.
6
A comparison of clinical-pathological characteristics between symptomatic and interval breast cancer.有症状乳腺癌与间期乳腺癌临床病理特征的比较。
Breast. 2015 Jun;24(3):278-82. doi: 10.1016/j.breast.2015.02.032. Epub 2015 Mar 11.
7
[Diagnostic value of ADC and rADC of diffusion weighted imaging in malignant breast lesions].[扩散加权成像的表观扩散系数（ADC）和相对表观扩散系数（rADC）在乳腺恶性病变中的诊断价值]
Zhonghua Zhong Liu Za Zhi. 2010 Mar;32(3):217-20.
8
Discordant HER2 immunohistochemical expression and gene amplification in ductal carcinoma in situ - evaluating HER2 in synchronous in-situ and invasive carcinoma.导管原位癌中HER2免疫组化表达与基因扩增不一致——评估同步原位癌和浸润性癌中的HER2
Histopathology. 2019 Jan;74(2):358-362. doi: 10.1111/his.13731. Epub 2018 Oct 29.
9
How to prevent invasive breast cancer: detect and excise duct carcinoma in situ.如何预防浸润性乳腺癌：检测并切除导管原位癌。
J Surg Oncol. 1998 Oct;69(2):60-2. doi: 10.1002/(sici)1096-9098(199810)69:2<60::aid-jso2>3.0.co;2-3.
10
A N0 Predicting Model for Sentinel Lymph Node Biopsy Omission in Early Breast Cancer Upstaged From Ductal Carcinoma in Situ.一种用于预测原位导管癌分期上调的早期乳腺癌前哨淋巴结活检遗漏的N0预测模型。
Clin Breast Cancer. 2020 Jun;20(3):e281-e289. doi: 10.1016/j.clbc.2019.11.011. Epub 2019 Dec 6.
引用本文的文献
1
Joint Entropy-Assisted Graphene Oxide-Based Multiplexing Biosensing Platform for Simultaneous Detection of Multiple Proteases.基于联合熵辅助的石墨烯氧化物的多重生物传感平台用于同时检测多种蛋白酶。
Anal Chem. 2020 Nov 17;92(22):15042-15049. doi: 10.1021/acs.analchem.0c03007. Epub 2020 Oct 29.
2
ADAM10 Sheddase Activity is a Potential Lung-Cancer Biomarker.ADAM10 蛋白酶活性是一种潜在的肺癌生物标志物。
J Cancer. 2018 Jun 23;9(14):2559-2570. doi: 10.7150/jca.24601. eCollection 2018.
3
ADAM12 Is a Novel Regulator of Tumor Angiogenesis via STAT3 Signaling.ADAM12 通过 STAT3 信号通路调控肿瘤血管生成。
Mol Cancer Res. 2017 Nov;15(11):1608-1622. doi: 10.1158/1541-7786.MCR-17-0188. Epub 2017 Aug 1.
4
ADAM12 is a prognostic factor associated with an aggressive molecular subtype of high-grade serous ovarian carcinoma.ADAM12是一种与高级别浆液性卵巢癌侵袭性分子亚型相关的预后因素。
Carcinogenesis. 2015 Jul;36(7):739-47. doi: 10.1093/carcin/bgv059. Epub 2015 Apr 29.
5
Matrix metalloproteinase-9 involvement in the structural plasticity of dendritic spines.基质金属蛋白酶-9参与树突棘的结构可塑性。
Front Neuroanat. 2014 Jul 10;8:68. doi: 10.3389/fnana.2014.00068. eCollection 2014.
6
Urinary concentrations of ADAM 12 from breast cancer patients pre- and post-surgery vs. cancer-free controls: a clinical study for biomarker validation.乳腺癌患者手术前后与无癌对照者尿液中ADAM 12的浓度：一项生物标志物验证的临床研究
J Negat Results Biomed. 2014 Apr 1;13:5. doi: 10.1186/1477-5751-13-5.
7
ADAM8 expression in invasive breast cancer promotes tumor dissemination and metastasis.ADAM8 在浸润性乳腺癌中的表达促进肿瘤的扩散和转移。
EMBO Mol Med. 2014 Feb;6(2):278-94. doi: 10.1002/emmm.201303373. Epub 2013 Dec 27.
8
A disintegrin and metalloproteinase-12 (ADAM12): function, roles in disease progression, and clinical implications.解整合素金属蛋白酶12（ADAM12）：功能、在疾病进展中的作用及临床意义
Biochim Biophys Acta. 2013 Oct;1830(10):4445-55. doi: 10.1016/j.bbagen.2013.05.011. Epub 2013 May 13.
9
The synthesis and application of Fmoc-Lys(5-Fam) building blocks.Fmoc-Lys(5-Fam) 构建模块的合成与应用。
Biopolymers. 2013 Jul;100(4):347-55. doi: 10.1002/bip.22222.
10
Chemical biology for understanding matrix metalloproteinase function.化学生物学在理解基质金属蛋白酶功能中的作用。
Chembiochem. 2012 Sep 24;13(14):2002-20. doi: 10.1002/cbic.201200298. Epub 2012 Aug 30.
本文引用的文献
1
Proteolytic Activity Matrix Analysis (PrAMA) for simultaneous determination of multiple protease activities.蛋白酶活性矩阵分析（PrAMA）用于同时测定多种蛋白酶活性。
Integr Biol (Camb). 2011 Apr;3(4):422-38. doi: 10.1039/c0ib00083c. Epub 2010 Dec 23.
2
Mammary gland reprogramming: metalloproteinases couple form with function.乳腺重编程：金属蛋白酶将形态与功能联系起来。
Cold Spring Harb Perspect Biol. 2011 Apr 1;3(4):a004333. doi: 10.1101/cshperspect.a004333.
3
Expression profiles and clinical correlations of degradome components in the tumor microenvironment of head and neck squamous cell carcinoma.肿瘤微环境中降解组成分在头颈部鳞状细胞癌中的表达谱及临床相关性。
Clin Cancer Res. 2010 Apr 1;16(7):2022-35. doi: 10.1158/1078-0432.CCR-09-2525. Epub 2010 Mar 21.
4
Fluorescent substrates useful as high-throughput screening tools for ADAM9.用作ADAM9高通量筛选工具的荧光底物。
Comb Chem High Throughput Screen. 2010 May;13(4):358-65. doi: 10.2174/138620710791054259.
5
ADAMs and ADAMTSs in cancer.癌症中的解聚素和金属蛋白酶（ADAMs）及含血小板反应蛋白基序的解聚素样金属蛋白酶（ADAMTSs）
Br J Biomed Sci. 2009;66(2):117-28. doi: 10.1080/09674845.2009.11730257.
6
Extracellular and cell surface proteases in wound healing: new players are still emerging.细胞外和细胞表面蛋白酶在伤口愈合中的作用：新的角色仍在不断涌现。
Eur J Dermatol. 2009 Nov-Dec;19(6):552-64. doi: 10.1684/ejd.2009.0770. Epub 2009 Jul 22.
7
Unraveling metalloproteinase function in skeletal biology and disease using genetically altered mice.利用基因工程小鼠解析金属蛋白酶在骨骼生物学和疾病中的功能。
Biochim Biophys Acta. 2010 Jan;1803(1):121-32. doi: 10.1016/j.bbamcr.2009.07.002. Epub 2009 Jul 17.
8
Tumor-specific urinary matrix metalloproteinase fingerprinting: identification of high molecular weight urinary matrix metalloproteinase species.肿瘤特异性尿基质金属蛋白酶指纹图谱：高分子量尿基质金属蛋白酶种类的鉴定
Clin Cancer Res. 2008 Oct 15;14(20):6610-7. doi: 10.1158/1078-0432.CCR-08-1136.
9
The ADAM metalloproteinases.ADAM金属蛋白酶
Mol Aspects Med. 2008 Oct;29(5):258-89. doi: 10.1016/j.mam.2008.08.001. Epub 2008 Aug 15.
10
Matrix metalloproteinase-9 (MMP-9) immunoreactive protein in urinary bladder cancer: a marker of favorable prognosis.基质金属蛋白酶-9（MMP-9）在膀胱癌中的免疫反应性蛋白：一种预后良好的标志物。
Anticancer Res. 2008 May-Jun;28(3B):1757-61.
Zotero 插件